ArticleAnnals of the New York Academy of Sciences2019
Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4
Article in Annals of the New York Academy of Sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Research progress and the prospect of using single-cell sequencing technology to explore the characteristics of the tumor microenvironment.Genes & diseases · 2025Review
- Pancreatic stellate cells and the interleukin family: Linking fibrosis and immunity to pancreatic ductal adenocarcinoma (Review).Molecular medicine reports · 2024Review
- Article
- Impaired function of dendritic cells within the tumor microenvironment.Frontiers in immunology · 2023Review
- VEGF promotes diabetic retinopathy by upregulating the PKC/ET/NF-κB/ICAM-1 signaling pathway.European journal of histochemistry : EJH · 2022Article
- The Role of Immunotherapy in Pancreatic Cancer.Current oncology (Toronto, Ont.) · 2022Review
- The Era of Cytotoxic CD4 T Cells.Frontiers in immunology · 2022Review
- Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer.Frontiers in immunology · 2022Review
- Review
- Development of Immunotherapy Combination Strategies in Cancer.Cancer discovery · 2021Review
- Review
- A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.Oncoimmunology · 2021Article
- Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.The Lancet. Oncology · 2020Review
- MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.Seminars in immunology · 2020Review
- Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory.Cancer cell international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
One successful class of cancer immunotherapies, immune checkpoint inhibitory antibodies, disrupts key pathways that regulate immune checkpoints, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These agents unleash the potency of antigen-experienced T cells that have already been induced as a consequence of the existing tumor. But only 20% of cancers naturally induce T cells. For most cancers, vaccines are require to induce and mobilize T effector cells (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.